How Gut Bacteria Byproducts Trigger GLP-1 Release — And It's Not Through the Receptors Scientists Expected

The researchers used isolated perfused rat colons — an ex vivo preparation that preserves the colon's blood supply, nerve connections, and cellular architecture while allowing precise control over what the colon is exposed to. They infused SCFAs (acetate, propionate, butyrate) both luminally (from the gut side) and vascularly (through the blood supply) and measured GLP-1 and PYY secretion. They then used receptor-specific agonists, antagonists, ion channel blockers, and metabolic inhibitors to determine the exact mechanism driving hormone release.

This study challenges a widely held assumption in gut biology. Many researchers and supplement companies have promoted the idea that fiber and SCFAs boost GLP-1 through FFAR2/FFAR3 receptors. If the real mechanism is metabolic — SCFAs serving as fuel for colon cells — it changes how we think about designing dietary interventions, prebiotics, and microbiome therapies aimed at enhancing natural GLP-1 release. It also suggests that the specific type of SCFA matters: acetate and butyrate work, but propionate does not.

This study connects two of the hottest areas in metabolic research: the gut microbiome and GLP-1 biology. With GLP-1 drugs like semaglutide transforming obesity treatment, there's enormous interest in whether natural GLP-1 release can be enhanced through diet and microbiome manipulation. This research suggests that fiber fermentation products can indeed boost GLP-1, but the mechanism is fundamentally different than assumed — it's about cellular energy metabolism, not receptor activation. This distinction matters for anyone trying to develop microbiome-based approaches to metabolic disease.

This is an ex vivo rat colon study, which may not perfectly represent the intact human colon with its full complement of neural, hormonal, and immune inputs. The isolated preparation, while excellent for mechanistic studies, removes some physiological context. Results in rats may not directly translate to humans. The PYY response to SCFAs was only observed after cAMP enhancement, suggesting the baseline effect may be weaker than the GLP-1 response.